Kornimate/medical-research-clean huggingface dataset:
telehealth exercise training in peripheral arterial disease - text-pad

Conditions: Peripheral Arterial Disease; Intermittent Claudication; Behavior, Health; Exercise Intervention

Summary: peripheral arterial disease is a common, under-treated and under-researched issue. the vast majority of these patients often have multiple issues which can be improved with targeted behavioural change interventions. nice has recommended that supervised exercise is the mainstay of treatment for intermittent claudication (ischaemic muscle pain on walking due to blocked and narrowed arteries). however, in the vast majority of uk hospitals, this isn't undertaken, and with the issues around group-based sessions and repeated visits to hospitals, this treatment option is not available with the coronavirus pandemic. this is a single-centre randomised control trial in 60 patients with peripheral arterial disease attending the freeman hospital. patients will be randomised to either an enhanced behavioural change intervention targeting multiple health behaviours vs a simple walking intervention. also, some patients will be involved in focus groups to understand their experience of the intervention and whether it is feasible and acceptable, allowing changes to be made to the program. the primary outcome will be to assess the feasibility and acceptability of the program. we will also be assessing multiple secondary outcomes including functional capacity, quality of life, sleep quality and smoking and alcohol reduction.


Eligibility criteria:
inclusion criteria: * diagnosis of pad confirmed by ankle-brachial index \<0.90 in one or both limbs * age \>= 40 years * able to walk distance \>50m * live in an area deemed in lowest 30% of super output area from office of national statistics exclusion criteria: * chronic limb threatening ischemia * short claudication distance \<50m * severe heart disease (grade iii or iv, new york heart association) * severe ischemic or haemorrhagic stroke or neurodegenerative diseases * severe hypertension (systolic blood pressure of more than 180 mm hg, and a diastolic * blood pressure of more than 100 mm hg) * uncontrolled cardiac arrhythmias (unstable angina during the previous month and * myocardial infarction during the previous month) * a resting heart rate of more than 120 beats per minute * has already undergone angioplasty, bypass or other surgical intervention for pad * other severe comorbid conditions preventing the ability to engage in physical activity, * inability or unwillingness to undertake the commitments of the study
asthma control study

Conditions: Childhood Asthma

Summary: the "digital health tool for parental management of childhood asthma -- impact on asthma control test scores" study is a 16 week, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the tueo health program on asthma control as indicated by change in baseline and study end (week 16) score on the childhood asthma control test score (ages 6- under 12 years) and the asthma control test (ages 12-17 years) in children with uncontrolled asthma as the primary study objective.


Eligibility criteria:
inclusion criteria: * parent has a child who is \> 6 and \< 17.5 years old * parent reports child has a diagnosis of asthma * child takes daily asthma controller medication * child has used rescue inhaler (e.g.albuterol, proair, etc) or nebulizer at least 2 times per week in the past 4 weeks * child sleeps on a toddler, single, or double bed by themselves * child will live in the same home for the majority of the next 16 weeks * parent is \> 18 years old exclusion criteria: * child's asthma has been controlled over the past 4 weeks * child has any of the following conditions: sleep apnea, congenital heart disease, cardiac arrhythmias, or any other heart abnormalities, neurologic conditions including seizures, cerebral palsy, muscular dystrophy, genetic conditions or developmental disorders, autism, other major medical condition * child is currently pregnant * child was born premature (earlier than 36 weeks) * parent is not fluent in english * no in-home wifi * parent does not use an android phone as their primary phone * in a household with an existing enrolled participant in the study, even for a different child (e.g. only one child in a household may have questions reported back to the researchers by their parent) * lives in hawaii or alaska
intubation with different angled intubation tubes using c-macr d blade videolaringoscope;

Conditions: Intubation; Difficult or Failed; Sore-throat; Hoarseness

Summary: in this study we compared post-operative sore throat, ease and time of intubation, hoarseness, subglottic damage and hemodynamic changes to orotracheal intubation using three different intubation stylets with c-mac r videolaryngoscope d- blade.

in this study we compared the ease of intubation, time needed for intubation, subglottic damage, postoperaitve sore throat, hoarseness and hemodynamic response to orotracheal intubation using three different intubation stylets with c-mac r videolaryngoscope d- blade. after the approval of the ethics committee, patients were randomized into three groups with closed envelope technique. in group a endotracheal tube (ett) is shaped into an angel of 90 degrees, in group b 80 degrees and in group c 60 degrees with three different stylets. laryngoscopy was performed using d-blade in all 3 groups. heart rate and blood pressure before and after intubation, time from the entrance of the laryngoscope into the mouth to the passage of the vocal cords, time from the appearance of the cords to intubation, cormack-lehane (c-l) classification were recorded. subglottic damage was examined with fiberoptic bronchoscope. patients were evaluated regarding postoperative sore throat and hoarsness at 30 minutes, 4, 12, 24 hours postoperatively.

Eligibility criteria:
inclusion criteria: * asa score i-ii * elective operations * supine pozition * 18-65 years * no history of surgery in the last 6 months * no history of airway related surgery * no anticipated difficult airway exclusion criteria: * abdomen, thorax, head-neck surgeries * smoker * chronic alcohol abuse * occupational inhaler agent exposure * patients with malignancies * patients with a history of radiotheraphy to head-neck region * patients with congenital anomalies at head-neck region * patients with diagnosed abnormalites of head -neck movements * non-cooperatied patients * non-oriented patients

Keywords: videolaryngoscope, intubation c-mac r videolaryngoscope, d- blade subglottic damage postoperative sore throat, hoarsness
preoperative imaging in retroperitoneal sarcoma

Conditions: Cancer

Summary: this is a prospective observational study in which patients with untreated retroperitoneal sarcoma will have magnetic resonance imaging (mri) prior to surgery. in addition, patients who will be undergoing pre-operative radiotherapy will have an additional mri scan at two weeks post radiotherapy. for both groups, the magnetic resonance images will be correlated with tumour pathology. the study hypothesis is that magnetic resonance imaging will provide a more accurate assessment of tumour volume and local staging than ct and will identify areas of altered oxygenation, cellularity and perfusion which change in response to radiotherapy before tumour shrinkage occurs.


Eligibility criteria:
inclusion criteria: * patients with retroperitoneal sarcomas planned for surgical resection +/- preoperative radiotherapy. exclusion criteria: * mri incompatible metal implants * claustrophobia

Keywords: retroperitoneal sarcoma magnetic resonance imaging
study to evaluate safety & effectiveness of spinal sealant

Conditions: Cerebrospinal Fluid Leakage, Subdural

Summary: to evaluate a spinal sealant as an adjunct to sutured dural repair compared to standard of care techniques.

neurosurgical procedures in the spine often involve incision of the dura mater to access the spinal cord. if the dural incision is not properly repaired and watertight closure is not achieved cerebrospinal fluid (csf) can escape presenting a risk for significant morbidity. the most frequent complication of csf leak is recurring headache complicated with symptoms of nausea and vomiting. furthermore fluid collection under skin prevents proper wound healing and may lead to wound breakdown and infection of the incision or both. persistent csf leak has also been associated with the development of cerebellar hemorrhage and subdural hematoma. primary repair and watertight closure are paramount to minimizing risk and sequelae associated with csf leak.

Eligibility criteria:
inclusion criteria: * subjects scheduled for a spinal procedure that requires a dural incision

Keywords: prevention of csf leak
a safety and tolerability study of zerenex (ferric citrate) in patients with end-stage renal disease (esrd)

Conditions: Hyperphosphatemia; End-stage Renal Disease

Summary: this study is to evaluates the safety and tolerability of zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with end-stage renal disease.

the purpose of this study is to evaluate the safety and tolerability of zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with end-stage renal disease. these patients will be switched to zerenex™ from their current high dose of phosphate binder and, based on their serum phosphorus levels, will be titrated up from 3.4g/day of zerenex™ to maximum tolerated and safe doses of zerenex™. doses will be adjusted weekly, based on serum phosphorus levels, with the maximum dose administered being approximately 12g/day.

Eligibility criteria:
inclusion criteria: * males and non-pregnant, nonlactating females * age \> 18 years * on thrice weekly hemodialysis for at least the previous 3 months prior to randomization * phosphorous levels ≥3.5mg/dl at screening visit * on at least 12 tablets/capsules/day of calcium acetate (667mg), calcium carbonate (500mg), lanthanum carbonate (500mg), sevelamer hydrochloride (800mg or two 400mg tablets), or any combination of these agents * serum ferritin \<1000micrograms/l and transferrin saturation (tsat) \<50% * willing to be discontinued from current phosphate binder(s) and initiated on zerenex * willing and able to give informed consent exclusion criteria: * parathyroidectomy within 6 months prior to screening * actively symptomatic gi disease such as peptic ulcer disease, gastro esophageal reflux, diverticulosis, irritable bowel syndrome (treated asymptomatic is permitted) * history of documented inflammatory bowel disease or erosive esophagitis * serum phosphorus levels \>10.0 mg/dl documented in the 3 monthly laboratories (done routinely in the dialysis unit) in the 3 months prior to the screening visit * history of multiple drug allergies * history of malignancy in the last 5 years (treated cervical or skin cancer may be permitted if approved by ccc) * previous intolerance to oral ferric citrate * absolute requirement for oral iron therapy * absolute requirement for vitamin c (multivitamins \[neprocaps, renaphro, etc.\] allowed) * absolute requirement for calcium, magnesium, or aluminum containing drugs with meals * psychiatric disorder that interferes with the patient's ability to comply with the study protocol * inability to tolerate oral drug intake * planned surgery or hospitalization during the study (scheduled outpatient access surgery allowed) * any other medical condition that renders the patient unable to or unlikely to complete the study or that would interfere with optimal participation in the study or produce significant risk to the patient * receipt of any investigational drug within 30 days of randomization * inability to cooperate with study personnel or history of noncompliance

Keywords: esrd end-stage renal disease end stage renal disease hemodialysis dialysis kidney failure renal failure kidney renal phosphate binder phosphorus
high-dose chemotherapy and radiation therapy followed by peripheral stem cell transplantation in treating patients with acute leukemia in remission

Conditions: Bone Marrow Ablation; Leukemia

Summary: rationale: drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. purpose: phase ii trial to study the effectiveness of high-dose radiation therapy and etoposide followed by peripheral stem cell transplantation in treating patients with acute leukemia.

objectives: i. evaluate the efficacy of myeloablative total-body irradiation and etoposide followed by autologous peripheral blood stem cell (pbsc) transplantation in prolonging the disease-free survival of patients with acute leukemia. ii. investigate the ability of growth factor-primed pbsc to provide hematopoietic reconstitution following myeloablative therapy. outline: patients are treated on regimen a, then regimen b. regimen a: stem cell mobilization. granulocyte colony stimulating factor (amgen), g-csf, nsc-614629. regimen b: radiotherapy and myeloablative chemotherapy with hematopoietic rescue. total-body irradiation, tbi (high-energy electrons used for lung boost); and etoposide, vp-16, nsc-141540; with peripheral blood stem cells, pbsc; g-csf. projected accrual: up to 45 patients will be studied over approximately 3 years.

Eligibility criteria:
disease characteristics: previously diagnosed acute leukemia in one of the following categories: acute myelogenous leukemia (any subtype) in first or subsequent remission ph+ acute lymphoblastic leukemia (all) in first or greater remission ph- all in second or subsequent remission cellular marrow with no morphologic evidence of residual leukemia within approximately 2 weeks of cryopreservation negative csf cytology required of all patients allogeneic marrow transplant considered for patients under age 55 with a healthy hla-identical family member available patient characteristics: age: over 16 to 65 performance status: not specified hematopoietic: wbc greater than 3,500/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin less than 2.0 mg/dl renal: creatinine no greater than 1.5 mg/dl or creatinine clearance at least 60 ml/min cardiovascular: lvef at least 50% by muga or normal on echocardiogram pulmonary: dlco at least 50% of predicted other: hiv seronegative no uncontrolled infection negative pregnancy test required of fertile women prior concurrent therapy: see disease characteristics

Keywords: adult acute myeloid leukemia in remission adult acute lymphoblastic leukemia in remission adult acute erythroid leukemia (m6) adult acute myeloblastic leukemia without maturation (m1) adult acute myeloblastic leukemia with maturation (m2) adult acute promyelocytic leukemia (m3) adult acute myelomonocytic leukemia (m4) adult acute monoblastic leukemia (m5a) adult acute megakaryoblastic leukemia (m7) adult acute monocytic leukemia (m5b) bone marrow ablation adult acute minimally differentiated myeloid leukemia (m0)
a 52-week open-label safety study of pd 0332334 in subjects with generalized anxiety disorder (gad)

Conditions: Generalized Anxiety Disorder

Summary: this study will assess the long-term safety and tolerability of 350 to 600 mg/day of pd 0332334 administered in split dose (twice daily) in subjects with generalized anxiety disorder.

termination reason: on february 23rd 2009, a decision to terminate further development for pd 0332334 was communicated to investigators in this study. the decision to terminate this study was not based on any safety concerns.

Eligibility criteria:
inclusion criteria: * subjects must have completed all phases of one of the four preceding double-blind gad studies. * female must continue to use adequate birth control methods and have a negative serum pregnancy test within 14 days prior to starting open label treatment. exclusion criteria: * subjects who experienced a serious adverse event during the preceding double-blind efficacy study that was judged to be related to study medication by the investigator or the sponsor's medical monitor. * individuals who have an ongoing, unresolved, clinically significant medical problem that, in the judgment of the investigator or the sponsor's medical monitor, would make it unsafe for the subject to participate in the study. * serious suicidal risk per the clinical investigators's judgement.

Keywords: generalized anxiety disorder
pioglitazone and serum asymmetric dimethylarginine (adma) in patients with diabetes

Conditions: Diabetes

Summary: specific aims 1. to determine whether pioglitazone will reduce levels of asymmetric dimethylarginine(adma) in patients with diabetes. 2. to determine whether nitric oxide(nox) products are increased with pioglitazone treatment. 3. to determine whether pioglitazone reduces oxidative stress (f2-isoprostanes).

the primary purpose of this study is to determine whether treatment with pioglitazone can reduce serum levels of asymmetric dimethylarginine (adma) in patients with adult diabetes. recent research has found that elevated serum adma is associated with increased cardiovascular events and mortality, particularly in people with diabetes (boger 2005, zoccali 2006, ueda 2007). adma, by mediating nitric oxide (no) availability, may trigger pro-atherogenic effects. high plasma concentration of this substance has been associated with intima-media thickening, left ventricular hypertrophy and all-cause and cardiovascular mortality in patients with end-stage renal disease, and associated with increased cardiovascular events in patients with diabetes (kryzazanowska 2007). the result of higher levels of adma and reduced output of no increases vasoconstriction, increases inflammation, and interferes with endothelial function. preliminary studies indicate that pioglitazone may reduce adma levels, and thus lower cardiovascular risk.thus, this protocol will test whether pioglitazone can reduce adma levels in adult patients with diabetes.

Eligibility criteria:
inclusion criteria: * adults age 40--75 years-of-age, non-pregnant * informed consent * history of type 2 diabetes mellitus * stable weight for the last 3 months (no change greater than +5% of body weight) * adma \> 0.50 µm/l (mean of non-diabetic reference group) (devangelio 2007) * on stable medical therapy for at least 3 months * a working telephone exclusion criteria: * any history of known coronary heart disease, including a history of congestive heart failure, myocardial infarction, coronary re-vascularization, or stroke * pregnancy * chronic kidney disease, serum creatinine \>2.0mg/dl, chronic liver disease, or uncontrolled hypertension (\>160/100). * current participation in a formal weight loss program or planning to start such a program during the next 3 months * collagen vascular disease, infection, or other inflammatory condition * electrocardiogram (ekg) evidence of ischemia or infarction * macular edema (swelling of the back of the eye), recent excessive weight gain (over 5% of weight in 30 days), elevated liver function tests \> 2.5 x the upper limit, or history of osteoporosis

Keywords: cardiovascular risk biological markers
impact of a proactive strategy of general practitioners on crc screening

Conditions: Colorectal Cancer

Summary: in this registry-based cluster randomized controlled trial, we will assess the impact of a proactive strategy of general practitioners (gp) who will systematically provide screening kits of colorectal cancer (crc) to all patients of even age (50, 52, 54...up to 74 years) versus usual practice where the eligible population receive an invitation letter to visit the general practitioner and receive the screening kit.

colorectal cancer is one of the leading causes of cancer and death in france in both men and women. the generalized screening rate is about 30% in france, far from the expected 65%, despite the fact that screening is free and a letter of invitation is sent to the individual's home, and despite the financial incentives provided to the practitioner. different studies have looked for the causes of non-implementation by the individual: negligence, "dirty"; forgetfulness, and the practitioner: organizational problem, communication problem. a few intervention studies have been carried out with little success: sending the invitation to the individual's home, sending a letter of reminder, sending a letter of general information on screening to the practitioner, sending the list of patients who have not taken the test to the practitioner allows for a few percent improvement in screening. in this registry-based cluster randomized controlled trial, we will assess the impact of a proactive strategy of general practitioners who will systematically provide screening kits of colorectal cancer to all patients of even age (50, 52, 54 years...up to 74 years) versus usual practice where the eligible population receive an invitation letter to visit the general practitioner and receive the screening kit. the screening rate will be calculated for each arm at the end of the 2-year study with data from the health insurance.

Eligibility criteria:
inclusion criteria: - medical practices in aquitaine region and their visiting patients eligible for colorectal cancer screening individuals aged between 50 and 74 years at intermediate risk of colorectal cancer). exclusion criteria: * medical practices with less than five individual eligible for colorectal cancer screening. * visiting patients aged less than 50 years or more than 74 years or at high or very high risk of colorectal cancer.

Keywords: colorectal cancer screening general practitioner social health inequalities
cognitive behavioral suicide prevention for psychosis: aim 1

Conditions: Suicide; Psychosis

Summary: the investigators are modifying and testing the preliminary effectiveness and implementation of a cognitive behavioral suicide prevention for psychosis (cbspp) intervention. in this phase of the study, cbspp will be tested in an initial open trial (n = 10) to examine its feasibility and acceptability. investigators will recruit clients receiving services at a community mental health setting who have a schizophrenia spectrum disorder and recent suicidal thoughts and behaviors to receive the behavioral intervention for 10-weeks. providers will be recruited and trained to deliver the intervention. both clients and providers will be assessed at baseline to test our approach to measurement prior to the aim 2 rct (registered separately). clients will be assessed at three additional timepoints (middle of treatment, end of treatment, and 2 months after treatment ends.


Eligibility criteria:
inclusion criteria: * schizophrenia spectrum disorder * suicide ideation and/or attempt within 3 months of screening * ability to speak and read in english * 18 to 65 years of age exclusion criteria: * requiring emergency care (e.g. imminent plan to harm self) as determined by trained research staff administering the columbia-suicide severity rating scale (c-ssrs) * inappropriate for behavioral treatment according to own judgment in consultation with a treating clinician cmh * impaired capacity (cognitive capacity)

Keywords: cognitive behavioral therapy suicide prevention community mental health